Hematopoietic Stem Cell Transplant for Dyskeratosis Congenita or Severe Aplastic Anemia
Key facts
- Who runs it
- Masonic Cancer Center, University of Minnesota
- Where
- Minneapolis, United StatesSee the site
- Trial code
- Status
- Completed
- People taking part
- 61 people enrolled
- Started
- 10 Jan 2015
- Ended
- 11 Mar 2025
- Type of study
- Interventional, 5 groups
- Treatments tested
- Alemtuzumab
- Fludarabine
- Cyclophosphamide
- Total Body Irradiation
- Stem Cell Transplant
- Anti-thymocyte globulin
- Record updated
- 8 May 2025
Who can take part
- Age
- 0 years to 70 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (18)Hide the full registry criteria
Who can take part
- Aged 0 - 70 years
- Acceptable hematopoeitic stem cell donor
- Dyskeratosis Congenita (DC) with evidence of BM failure defined as:; requirement for red blood cell and/or platelet transfusions or; requirement for G-CSF or GM-CSF or erythropoietin or; refractory cytopenias having one of the following three; platelets <50,000/uL or transfusion dependent; absolute neutrophil count <500/uL without hematopoietic growth factor support; hemoglobin <9g/uL or transfusion dependent
- Diagnosis of DC with a triad of mucocutaneous features:; oral leukoplakia; nail dystrophy; abnormal reticular skin hyperpigmentation, or
- Diagnosis of DC with one of the following:; short telomeres (under a research study); mutation in telomerase holoenzyme (DKC1, TERT, TERC, NOP10, NHP2, TCAB1); mutation in shelterin complex (TINF2); mutation in telomere-capping complex (CTC1)
- Severe Aplastic Anemia (SAA) primary transplant with evidence of BM failure:; Refractory cytopenia defined by bone marrow cellularity <50% (with < 30% residual hematopoietic cells)
- Diagnosis of SAA with refractory cytopenias having one of the following three:; platelets <20,000/uL or transfusion dependent; absolute neutrophil count <500/uL without hematopoietic growth factor support; absolute reticulocyte count <20,000/uL
- Severe Aplastic Anemia (SAA) requiring a 2nd transplant; Graft failure as defined by blood/marrow chimerism of < 5%
- Early myelodysplastic features
- With or without clonal cytogenetic abnormalities
- Adequate organ function defined as:; cardiac: left ventricular ejection fraction ≥ 35% with no evidence of decompensated heart failure; pulmonary: DLCO ≥30% predicted, no supplemental oxygen requirement; renal: Glomerular filtration rate (GFR) ≥30% predicted
- Voluntary written consent
Who cannot take part
- Prior radiation therapy (applies to SAA patients only)
- Acute hepatitis or evidence of moderate or severe portal fibrosis or cirrhosis on biopsy
- Uncontrolled infection
- Pregnant or lactating
- Diagnosis of Fanconi anemia based on DEB
- Diagnosis of dyskeratosis congenita with advanced MDS or acute myeloid leukemia with >30% blasts
Where in United States
- University of Minnesota Medical Center, FairviewMinneapolis, United States
About the trial
What the trial wants to find out
Fludarabine-based preparative regimen followed by an allogeneic hematopoietic stem cell transplant using related or unrelated donor in persons 0-70 years of age diagnosed with dyskeratosis congenita or severe aplastic anemia who have bone marrow failure characterized by a requirement for red blood cell and platelet transfusions. Three different preparative regimens are included based on disease and donor type.
The 5 groups in the trial
- Arm A Dyskeratosis Congenita (DKC) (non-haploidentical donor)Treatment being tested
Fludarabine based preparative regimen, including alemtuzumab, cyclophosphamide, fludarabine, followed by stem cell transplant for the treatment of dyskeratosis congenita.
Treatment: Alemtuzumab, Fludarabine, Cyclophosphamide, and Stem Cell Transplant
- Arm B: Severe Aplastic Anemia (SAA ) (non-matched related, non-haploidentical donor)Treatment being tested
Fludarabine based preparative regimen which includes: cyclophosphamide, fludarabine, rabbit ATG and total body irradiation. Followed by stem cell transplant.
Treatment: Alemtuzumab, Fludarabine, Cyclophosphamide, Total Body Irradiation, Stem Cell Transplant, and Anti-thymocyte globulin
- Arm C: Severe Aplastic Anemia (matched related donor)Treatment being tested
Fludarabine based preparative regimen which includes: cyclophosphamide, fludarabine, rabbit ATG and total body irradiation. Followed by stem cell transplant.
Treatment: Alemtuzumab, Fludarabine, Cyclophosphamide, Total Body Irradiation, Stem Cell Transplant, and Anti-thymocyte globulin
- Arm D: Dyskeratosis Congenita (DKC), PTCy platformTreatment being tested
Fludarabine based preparative regimen, including alemtuzumab, cyclophosphamide, fludarabine, followed by stem cell transplant for the treatment of dyskeratosis congenita.
Treatment: Alemtuzumab, Fludarabine, Cyclophosphamide, and Stem Cell Transplant
- Arm E: Severe Aplastic Anemia (SAA), PTCy platformTreatment being tested
Fludarabine based preparative regimen which includes: cyclophosphamide, fludarabine, rabbit ATG and total body irradiation. Followed by stem cell transplant.
Treatment: Alemtuzumab, Fludarabine, Cyclophosphamide, Total Body Irradiation, Stem Cell Transplant, and Anti-thymocyte globulin
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 8 May 2025